NOT KNOWN FACTUAL STATEMENTS ABOUT ABBV-744 PRECLINICAL STUDIES AND RESULTS

The current work examined the potential of making use of ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant additionally palbociclib. ARV-825 was effective in both equally p53 wild-type (WT) breast tumor cells and in cells lacking functional p53 either alone or in combination with tamoxifen, even though the effectiveness